Vimarsana
Biggest News Aggregation in the World

Prescribing Informationfor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Prescribing Informationfor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Prescribing Informationfor Today - Breaking & Trending Today

Biogen Inc.: FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease - Vimarsana News

Biogen Inc.: FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Published: June 10, 2024

TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts

Source: finanznachrichten.de
Related Topics:
United KingdomHong KongUnited StatesSouth KoreaSaudi ArabiaGreat BritainChuck TrianoChristophera ViehbacherLinkedinand FacebookTsujim ProtofibrilsJack CoxHaruo NaitoJulie EdelmanDrug AdministrationEuropean UnionUnited Nations Sustainable Development Goals SdgsInvestor Relations DepartmentExchange CommissionEisai Co LtdNational Institutes Of HealthCommunications DepartmentWashington University School Of MedicineEisai Europe LtdNational Institute OnAlzheimer Clinical Trial Consortium
Teva Pharmaceutical Industries Limited: Teva and Alvotech Announce SIMLANDI (adalimumab-ryvk) Injection Now Available in the U.S. - Vimarsana News

Teva Pharmaceutical Industries Limited: Teva and Alvotech Announce SIMLANDI (adalimumab-ryvk) Injection Now Available in the U.S.

Published: May 21, 2024

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and

Source: finanznachrichten.de
Related Topics:
Republic OfUnited StatesUnited KingdomNew ZealandSouth KoreaHong KongYangtze RiverChina GeneralYael AshmanRobert WessmanEden KleinThomas RaineySanjeev SharmaSaval Latin AmericaKelley DoughertyTeva Pharmaceutical Industries LtdFuji Pharma Co Ltd JapanPharma Corporation CanadaLotus Pharmaceuticals Co LtdTeva PharmaceuticalsKamada LtdAbbvie Biotechnology LtdOaktree Acquisition CorpYangtze River Pharmaceutical Group Co LtdAlvotech Holdings
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status - Vimarsana News

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Published: May 15, 2024

TOKYO and CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated the rolling submission of a Biologics License Application to the...

Source: marketscreener.com
Related Topics:
South KoreaUnited KingdomUnited StatesSaudi ArabiaHong KongGreat BritainChuck TrianoHaruo NaitoJack CoxJulie EdelmanTsujim ProtofibrilsEisai IncWashington University School Of MedicineNational Institute OnDrug AdministrationNational Institutes Of HealthEuropean UnionEisai Co LtdUnited Nations Sustainable Development Goals SdgsAlzheimer Network Trials UnitBiogen IncExchange CommissionInvestor Relations DepartmentPrnewswire Eisai Co LtdPublic Relations Department
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy - Vimarsana News

bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy

Published: March 11, 2024

SOMERVILLE, Mass.--(BUSINESS WIRE)--Mar 11, 2024--

Source: eagletribune.com
Related Topics:
United StatesTom KlimaJess RowlandsExchange CommissionMichigan MedicaidState Medicaid AgenciesMedicaid InnovationGene Therapy Access Demonstration ModelMarketing Long Term Follow Up StudyPrescribing InformationforPrivate Securities Litigation Reform ActAnnual ReportQuarterly ReportsCurrent ReportsBusiness Wire
Alvotech and Teva Announce U.S. Approval of SIMLANDI® - Vimarsana News

Alvotech and Teva Announce U.S. Approval of SIMLANDI®

Published: February 24, 2024

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar...

Source: globenewswire.com
Related Topics:
South KoreaRepublic OfNew ZealandHong KongUnited KingdomYangtze RiverChina GeneralUnited StatesEden KleinYonatan BekerYael AshmanRobert WessmanSaval Latin AmericaKelley DoughertyEric HughesSanjeev SharmaOaktree Acquisition CorpLotus Pharmaceuticals Co LtdAbbvie Biotechnology LtdAlvotech HoldingsYangtze River Pharmaceutical Group Co LtdDrug AdministrationKamada LtdFuji Pharma Co Ltd JapanPharma Corporation Canada